Glycemic parameters
Biomarker1 paper1 finding
- Human trial1
Interventions
1UBT251
upin humans1
1 study
UBT251
upin humans1
UBT251 improves glycemic parameters in humans.
Human trialAdults with overweight or obesity without type 2 diabetes2 mg, 4 mg, or 6 mg once weekly24 weeks59.0% womensn = 205
A triple-target drug cut body weight by up to 19.7% in a trial · Cell metabolism · 7 Oct 2026
Latest
10Cell MetabolismHuman trial
A triple-target drug cut body weight by up to 19.7% in a trial
Average body weight fell between 13.6% and 19.7% across drug doses compared with 2.0% on placebo over 24 weeks.Average body weight fell between 13.6% and 19.7% across drug doses compared with 2.0% on placebo over 24 weeks.
Journal of the Formosan Medical AssociationReview
Taiwan joint consensus on the management of osteoporosis in patients with diabetes
ADA Scientific Sessions 2026 AbstractHumans
Addition of GLP-1 Analogs to DM1 Patients Using Automatic Insulin Delivery (AID) (MiniMed 780G): A Retrospective Real-Life Study
ADA Scientific Sessions 2026 AbstractHumans
Real-World Outcomes of Tirzepatide Combined with Personalized Lifestyle Modification in an Indian Population with Diabetes and Obesity
AHA Scientific Sessions 2025 AbstractHuman trial